Roberta Monteiro | Market Access and Commercial Director Brazil
Eisai

Roberta Monteiro, Market Access and Commercial Director Brazil, Eisai

Responsible for leading Market Access BU including Pricing, Reimbursement, Health Economics, Government Affairs and Advocacy. Also Commercial strategies and activities.

Master Degree in Pharmacoeconomic / Health Economics
Acted in the area of market access and pharmacoeconomics as independent consultant;
Worked in the market access areas at Wyeth / Pfizer, Lilly, Bristol in Brazil;
Currently Market Access and Commercial Director at Eisai Laboratórios Brazil;
More than 10 years in strategic work in market access focusing on the products life cycle, which provides updates, insights and recommendations.

Appearances:



Pharma Pricing & Market Access USA Day 1 @ 15:30

Brazil focus: Market access and value generation

  • Analyze what stakeholders in Brazilian healthcare can bring to the table to create business opportunities and provide value at the same time
  • Challenges can only be met together: Discover how helping partners keeps you one step ahead of future health trends
  • Find out how creating long-lasting relationships helps pinpoint business opportunities where there are common goals

Pharma Pricing & Market Access USA Day 2 @ 12:20

ROUND TABLES

1) Global Market Access For Orphan Drugs - How to include developing countries

  • Durhane Wong-Rieger, President, Canadian Organization for Rare Disorders
  • Ron Marchessault, Vice President, Value and Access, Specialty Care Sanofi Genzyme
  • Ramaiah Muthyala, President, Indian Organization for Rare Diseases
  • George Wyatt, Executive Senior Consultant, Innomar Strategies, Amerisource Bergen
  • Lisa Phelps, VP Policy, NORD National Organization for Rare Diseases
  • Meryem Nimour, VP- Medical Affairs Lead – Rare Disease- Emerging Markets, Pfizer
  • Pam Gavin, Chief Operating Officer, National Organization for Rare Diseases
2) Patient led Evidence - Discussing new levels of patient centricity in pricing models
  • Bert Vrijhoef, CIO & Senior Principal, Investigator, Panaxea & Maastricht University Medical Center
  • Lauren Bartolome, HEOR fellow, Novartis
  • Nneka Onwudiwe, PRO/PE Regulatory Review Officer, US Government​
3) I/O Pricing Models- New models to stumulate a fluctuating market
  • Bhakti Arondekar, Sr Director, Outcomes & Evidence, Oncology, Pfizer
  • Alberto Batista, HEOR fellow, Jefferson College of Population Health
  • Francisco Burgin, PGY-1 Managed Care Pharmacy Resident, Humana
4) Asian Access and Reimbursement- Discussing new developments in HTA in Asia
  • Jack Shea, Director Corporate Development, Merck
  • Sean McElligott, Director, Market Access, Janssen
  • Elizabeth Richardson, Managing Associate, Duke Margolis Center for Health Policy
5) Paying for gene therapy- Single fix medication and pricing models
  • John Maslowski, President and CEO, Fibrocell
  • Timothy Miller, President, CEO and Director, Abeona Therapeutics Inc
  • Christine Lu, Associate Professor, Harvard Medical School & Harvard Pilgrim Health Care Institute
  • Marianne Hamilton Lopez, Research Director, Duke-Robert J. Margoli Centre for Health Policy
6) Brazil Focus: Market Acess and Value Generation
  • Christina Matteucci, Market Access Head, Brazil, Bristol Myers Squibb
  • Roberta Monteiro, Market Access and Commercial Director, Eisai Brasil
7) Pluralistic approaches to value - Does the one size fits all approach still work?
  • Shanthy Krishnaraja, Global Head of Health Economics and Reimbursement Strategy, CSL Behring
  • Ashley John, Senior Specialist, Advocacy and Policy, American Academy of Dermatology

8) One payer systems - Consequences of implementation

  • Stephen Smith, Reimbursement Associate, Merck

Brazil Focus: Market access and value generation

back to speakers